PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Epidemiology, Children\'s Hospital Colorado, Aurora, Colorado, USA.\', \'Department of Pediatrics (Center for Cancer and Blood Disorders), University of Colorado School of Medicine and Children\'s Hospital Colorado, Aurora, Colorado, USA.\', \'Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children\'s Hospital Colorado, Aurora, Colorado, USA.\', \'Department of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado, USA.\', \'Children\'s Hospital Colorado and Adult and Child Center for Health Outcomes Research and Delivery Science, University of Colorado School of Medicine, Aurora, Colorado, USA.\', \'Department of Pathology and Laboratory Medicine, Children\'s Hospital Colorado, Aurora, Colorado, USA.\', \'Department of Pediatrics (Infectious Diseases), University of Colorado School of Medicine and Children\'s Hospital Colorado, Aurora, Colorado, USA.\', \'Department of Pediatrics (Infectious Diseases and Hospital Medicine and Epidemiology), University of Colorado School of Medicine and Children\'s Hospital Colorado, Aurora, Colorado, USA.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1002/pbc.29277
?:hasPublicationType
?:journal
  • Pediatric blood & cancer
is ?:pmid of
?:pmid
?:pmid
  • 34453477
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • SARS-CoV-2 persistence in immunocompromised children.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all